There are currently 35 active clinical trials seeking participants for Psoriasis research studies. The states with the highest number of trials for Psoriasis participants are Ontario, California, Florida and Texas.
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
NCT05635266
Recruiting
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/03/2024
Locations: Sanguine Biosciences, Waltham, Massachusetts
Conditions: Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Register for Updates
PatientSpot Formerly Known as ArthritisPower
NCT03840928
Recruiting
Patient Power is a patient research network and database (registry) to collect prospective information about demographics, self-reported diagnoses and medications, and willingness to participate in research from participants with rheumatoid arthritis (RA), spondyloarthritis (SpA), other musculoskeletal conditions, chronic neurological conditions like migraine, chronic pulmonary conditions like Chronic Obstructive Pulmonary Disease (COPD), asthma, autoimmune dermatological conditions such as psor... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
12/12/2023
Locations: Global Healthy Living Foundation, Upper Nyack, New York
Conditions: Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Register for Updates
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
NCT03240809
Recruiting
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
Gender:
ALL
Ages:
Between 6 years and 18 years
Trial Updated:
08/09/2023
Locations: Bausch Site 003, San Diego, California +4 locations
Conditions: Psoriasis
Register for Updates
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
NCT03987763
Recruiting
This study is to evaluate the safety, the systemic exposure of halobetasol propionate (HP), and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-122 lotion in pediatric participants with moderate to severe plaque psoriasis.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/25/2023
Locations: Bausch Site 11, Fountain Valley, California +7 locations
Conditions: Psoriasis
Register for Updates
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
NCT03988439
Recruiting
This study is to evaluate the safety, the systemic exposure, and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-118 lotion in pediatric participants with moderate to severe plaque psoriasis.
Gender:
ALL
Ages:
Between 4 years and 17 years
Trial Updated:
07/25/2023
Locations: Bausch Site 7, Doral, Florida +8 locations
Conditions: Psoriasis
Register for Updates
Psorcast Mobile Study
NCT05621369
Recruiting
The purpose of this study is to understand variation in the symptoms of psoriasis and psoriatic arthritis using simple, scalable smartphone-based measurements. This study uses an iPhone app to record these symptoms through questionnaires and sensors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2023
Locations: Sage Bionetworks, Seattle, Washington
Conditions: Psoriatic Arthritis, Psoriasis, Psoriatic Conditions, Dermatologic Disease, Rheumatologic Disease, Psoriatic Nail, Plaque Psoriasis, Joint Pain, Dactylitis
Register for Updates
Taltz in Combination With Enstilar for Psoriasis
NCT04372277
Recruiting
Enstilar in combination with Taltz for plaque psoriasis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2020
Locations: Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey
Conditions: Psoriasis
Register for Updates
Duobrii in Combination With Biologics
NCT04119102
Recruiting
12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2020
Locations: Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey
Conditions: Psoriasis
Register for Updates
ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
NCT04347473
Recruiting
Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/13/2020
Locations: Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey
Conditions: Psoriasis
Register for Updates
Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
NCT03827876
Recruiting
4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2019
Locations: Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey
Conditions: Psoriasis
Register for Updates
An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients
NCT03392337
Recruiting
A single center study of 30 patient receiving Narrowband UVB phototherapy three times weekly for 12 weeks. Patients will be evaluated through week 36 to evaluate maintenance of response.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2019
Locations: Elise Nelson, East Windsor, New Jersey
Conditions: Psoriasis
Register for Updates